Keyhaven Capital Partners has partnered with Miura Partners and Evolve Healthcare Partners to support their acquisition of HealthTech BioActives (HTBA), a global specialist in natural ingredients and active pharmaceutical production.
HTBA, headquartered in Barcelona, Spain, specialises in the research, development, and production of naturally derived ingredients, including citrus flavonoids and active forms of vitamin B12. These products cater to a diverse range of industries such as pharmaceuticals, health supplements, food and beverages, and livestock nutrition.
Known for its patented, sustainability-focused manufacturing processes that are solvent-free and carcinogen-free, HTBA’s global reach spans over 60 countries, with a state-of-the-art manufacturing facility in Murcia, Spain, and technical labs in Barcelona and Cincinnati, Ohio.
According to a press statement, this investment, Keyhaven’s third in 2024 and the tenth under its latest fund, aims to “drive both organic and inorganic growth for HTBA, strengthening its position as a leader in natural ingredients for health and food sectors”.
